Abstract: Low endotoxin fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising less than about 0.2, 0.18, 0.1, 0.01, 0.001, or 0.0005 endotoxin units (EU) per milligram of the fucan are disclosed. Methods and systems for removing or reducing the amount of endotoxins from a starting fucan composition are also disclosed.
Type:
Grant
Filed:
July 24, 2019
Date of Patent:
March 26, 2024
Assignee:
ARC Medical Inc.
Inventors:
Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
Abstract: High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60% w/w of the composition has a molecular weight above 100 kDa.
Type:
Application
Filed:
July 27, 2022
Publication date:
May 11, 2023
Applicant:
ARC Medical Inc.
Inventors:
Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun
Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.
Type:
Grant
Filed:
July 24, 2019
Date of Patent:
May 9, 2023
Assignee:
ARC Medical Inc.
Inventors:
Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
© 2024 Justia
